Direct Determination of Pb in Whole Blood by Graphite Furnace Atomic Absorption Spectro- photometry (GF-AAS)

Importance of the Topic

Lead is a persistent heavy metal with cumulative toxicity affecting multiple organ systems. Monitoring blood lead levels is critical for public health, guiding interventions to prevent neurological, hematological, cardiovascular, renal, and gastrointestinal damage. Rapid and accurate determination of lead in whole blood supports clinical diagnosis, environmental exposure assessment, and regulatory compliance.

Objective and Study Overview

This study presents a direct method for quantifying lead in whole blood using graphite furnace atomic absorption spectrophotometry. The goal is to streamline sample preparation, achieve low detection limits, and validate accuracy and precision against established advisory levels set by health authorities.

Methodology and Instrumentation

A matrix modifier was formulated by combining Triton X-100, ammonium phosphate, and nitric acid in deionized water. Calibration standards ranging from 0 to 60 ppb were prepared by diluting lead stock solutions into the modifier. Whole blood samples and spiked recovery controls were mixed at a ratio of 1 part blood to 9 parts modifier. Measurements were conducted on a Shimadzu AA-7000G equipped with a GFA-7000 graphite furnace atomizer and ASC-7000 autosampler. Key operating parameters included:

• Wavelength 283.3 nm
• Lamp current 10 mA
• Slit width 0.7 nm
• Background correction by deuterium lamp
• Platform-type graphite tube for uniform atomization
• Injection volume 10 µL

Temperature programming optimized pyrolysis and atomization steps to stabilize the lead signal and minimize matrix interference.

Key Results and Discussion

The calibration curve exhibited excellent linearity (r=0.9997) over the tested range. Spiked recovery tests at 10, 30, and 50 ppb yielded recoveries between 99 and 109 with relative standard deviations below 6. The platform-type tube design enabled controlled atomization at target temperatures while the matrix modifier enhanced lead release and prevented volatilization losses. Peak profiles confirmed consistent signal shapes for standards and samples.

Benefits and Practical Applications

This direct GF-AAS approach offers:

• Minimal sample preparation without digestion
• High sensitivity and accuracy for lead detection
• Reduced matrix interference through optimized modifier and furnace design
• Suitability for clinical, environmental, and forensic laboratories

Future Trends and Potential Applications

Advancements may include automation of sample handling, integration with microfurnace technology for lower volumes, development of novel modifiers to expand element scope, and coupling with separation techniques for speciation analysis. Emerging portable AAS instruments could enable on-site blood screening.

Conclusion

The described method demonstrates reliable, precise, and efficient determination of lead in whole blood using GF-AAS. The combination of a platform-type graphite tube and tailored matrix modifier achieves low detection limits and robust performance, aligning with public health monitoring requirements.

References

• World Health Organization. Brief Guide to Analytical Methods for Measuring Lead in Blood. 2011.
• Agency for Toxic Substances and Disease Registry. Lead Toxicity: U S Standards for Lead Levels.
• Centers for Disease Control and Prevention. The Lead Laboratory. 1997.